The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors.

The results are reported as nonsignificant (ns) at P > 0.05, significant (*) at 0.01 ≤ P < 0.05, very significant (**) at 0.001 ≤ P < 0.01, and extremely significant (***) at P < 0.001.

also in 7,074 other papers

Combining HBI-8000 with CTLA-4 Ab produced a highly significant delay in tumor progression, with 20% of tumor-bearing mice experiencing complete regression.

also in 127,188 other papers